RxDoctor Payments Data

Orlando Rodriguez, MD

Pulmonary Disease · Nashville, TNNPI 1336147685

Payments from drug & device makers

$10,001in general payments, 2019–2025

Across 405 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$1K
  • Boehringer Ingelheim$948
  • GSK$914
  • AstraZeneca$784
  • Actelion Pharmaceuticals US, Inc.$651
  • Insmed, Inc.$483
  • plus $5K from 42 others

What the payments were for

  • Travel & lodging$1,04210%
  • Food & beverage$8,79188%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,001 in reported general payments places this provider in the 65th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$146,858
Medicare patients
414
Services billed
1,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate24$310,767
XywavSodium,calcium,mag,pot Oxybate12$241,680
Prolastin CAlpha-1-Proteinase Inhibitor13$151,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$117,761
Pirfenidone25$94,777
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$35,934
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$34,379
Stiolto RespimatTiotropium Br/Olodaterol Hcl49$24,798
Combivent RespimatIpratropium/Albuterol Sulfate31$18,564
EliquisApixaban22$15,448
Breo ElliptaFluticasone/Vilanterol25$13,674
Arnuity ElliptaFluticasone Furoate48$12,794
Albuterol Sulfate HfaAlbuterol Sulfate271$8,113
SymbicortBudesonide/Formoterol Fumarate34$7,723
Fluticasone Propionate HfaFluticasone Propionate12$4,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat$948$354,128104 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$914$180,164299 claims
Grifols USA, LLCProlastin C$207$151,96813 claims
AstraZenecaBreztri Aerosphere, Symbicort$784$42,10267 claims
PfizerEliquis$53$15,44822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →